ERBB2 and cancer: Although HER2 status did not show an independent prognostic value for survival,26 for these HER2-positive cancers, as well as those with low HER2 expression, antibody–drug conjugates targeting HER2 are a promising therapeutic strategy, and trials are ongoing.27